ClinConnect ClinConnect Logo
Search / Trial NCT02304328

Impact of Herniation on WFNS Grading in Spontaneous Subarachnoid Hemorrhage - a SWISS SOS Observational Trial

Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Nov 25, 2014

Trial Information

Current as of June 03, 2025

Completed

Keywords

Sah Wfns H Wfns Grading

ClinConnect Summary

Background

Aneurysmal subarachnoid hemorrhage (SAH) is a severe disease affecting approximately 400 patients per year in Switzerland. Death and severe disability after spontaneous SAH are related to the initial severity of the bleeding. The scale which is most often used and recommended to grade the severity of SAH is the World Federation of Neurosurgical Societies scale. Besides the Glasgow Coma Scale as basis for the WFNS grading, the existence of a neurologic deficit is included in this scale. In general WFNS I-III patients are termed good grade and WFNS IV and V poor grade. Morbidity a...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Written informed consent of the patient or consent of patient's next of kin
  • Spontaneous SAH
  • Age: ≥18
  • Glasgow coma scale (GCS) ≤ 12. In intubated patients the GCS assessment will be performed after cessation of sedation or if not possible the last GCS score before intubation will be used
  • Exclusion Criteria
  • SAH due to any other cause or structural abnormality of the brain (trauma, dissection, arterio-venous malformation, dural arterio-venous fistula)
  • Foreseeable difficulties in follow-up due to geographic reasons (e.g., patients living abroad)

About Insel Gruppe Ag, University Hospital Bern

Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.

Locations

Basel, , Switzerland

St. Gallen, , Switzerland

Lausanne, , Switzerland

Zürich, , Switzerland

Aarau, , Switzerland

Genève, , Switzerland

Bern, , Switzerland

Lugano, , Switzerland

Patients applied

0 patients applied

Trial Officials

Christian Fung, MD

Principal Investigator

Insel Gruppe AG, University Hospital Bern

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials